Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jan;41(1):49–53. doi: 10.1128/aac.41.1.49

Once-daily gentamicin therapy for experimental Escherichia coli meningitis.

A Ahmed 1, M M París 1, M Trujillo 1, S M Hickey 1, L Wubbel 1, S L Shelton 1, G H McCracken Jr 1
PMCID: PMC163658  PMID: 8980753

Abstract

In vitro and in vivo studies have demonstrated that the bacteriologic efficacy of once-daily aminoglycoside therapy is equivalent to that achieved with conventional multiple daily dosing. The impact of once-daily dosing for meningitis has not been studied. Using the well-characterized rabbit meningitis model, we compared two regimens of the same daily dosage of gentamicin given either once or in three divided doses for 24 or 72 h. The initial 1 h mean cerebrospinal fluid (CSF) gentamicin concentration for animals receiving a single dose (2.9 +/- 1.7 micrograms/ml) was threefold higher than that for the animals receiving multiple doses. The rate of bacterial killing in the first 8 h of treatment was significantly greater for the animals with higher concentrations in their CSF (-0.21 +/- 0.19 versus -0.03 +/- 0.22 log10 CFU/ml/h), suggesting concentration-dependent killing. By 24h, the mean reduction in bacterial titers was similar for the two regimens. In animals treated for 72 h, no differences in bactericidal activity was noted for 24, 48, or 72 h. Gentamicin at two different dosages was administered intracisternally to a separate set of animals to achieve considerably higher CSF gentamicin concentrations. In these animals, the rate of bacterial clearance in the first 8 h (0.52 +/- 0.15 and 0.58 +/- 0.15 log10 CFU/ml/h for the lower and higher dosages, respectively) was significantly greater than that in animals treated intravenously. In conclusion, there is evidence of concentration-dependent killing with gentamicin early in treatment for experimental E. coli meningitis, and once-daily dosing therapy appears to be at least as effective as multiple-dose therapy in reducing bacterial counts in CSF.

Full Text

The Full Text of this article is available as a PDF (198.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barclay M. L., Begg E. J., Hickling K. G. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet. 1994 Jul;27(1):32–48. doi: 10.2165/00003088-199427010-00004. [DOI] [PubMed] [Google Scholar]
  2. Bates R. D., Nahata M. C. Once-daily administration of aminoglycosides. Ann Pharmacother. 1994 Jun;28(6):757–766. doi: 10.1177/106002809402800614. [DOI] [PubMed] [Google Scholar]
  3. Blaser J., König C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis. 1995 Dec;14(12):1029–1038. doi: 10.1007/BF01590935. [DOI] [PubMed] [Google Scholar]
  4. Blaser J., Stone B. B., Zinner S. H. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother. 1985 Mar;27(3):343–349. doi: 10.1128/aac.27.3.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Curl J. L., Curl J. S. Pharmacokinetics of gentamicin in laboratory rabbits. Am J Vet Res. 1988 Dec;49(12):2065–2067. [PubMed] [Google Scholar]
  6. Gilbert D. N. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991 Mar;35(3):399–405. doi: 10.1128/aac.35.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hieber J. P., Nelson J. D. A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med. 1977 Aug 25;297(8):410–413. doi: 10.1056/NEJM197708252970802. [DOI] [PubMed] [Google Scholar]
  8. Hodges G. R., Watanabe I., Singer P., Rengachary S., Reeves D., Jusetesen D. R., Worley S. E., Gephardt E. P., Jr Central nervous system toxicity of intraventricularly administered gentamicin in adult rabbits. J Infect Dis. 1981 Feb;143(2):148–155. doi: 10.1093/infdis/143.2.148. [DOI] [PubMed] [Google Scholar]
  9. Kovarik J. M., Hoepelman I. M., Verhoef J. Once-daily aminoglycoside administration: new strategies for an old drug. Eur J Clin Microbiol Infect Dis. 1989 Sep;8(9):761–769. doi: 10.1007/BF02185842. [DOI] [PubMed] [Google Scholar]
  10. Luer M. S., Hatton J. Vancomycin administration into the cerebrospinal fluid: a review. Ann Pharmacother. 1993 Jul-Aug;27(7-8):912–921. doi: 10.1177/106002809302700720. [DOI] [PubMed] [Google Scholar]
  11. Mattie H., Craig W. A., Pechère J. C. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989 Sep;24(3):281–293. doi: 10.1093/jac/24.3.281. [DOI] [PubMed] [Google Scholar]
  12. Powell S. H., Thompson W. L., Luthe M. A., Stern R. C., Grossniklaus D. A., Bloxham D. D., Groden D. L., Jacobs M. R., DiScenna A. O., Cash H. A. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis. 1983 May;147(5):918–932. doi: 10.1093/infdis/147.5.918. [DOI] [PubMed] [Google Scholar]
  13. Scheld W. M., Brown R. S., Jr, Sande M. A. Comparison of netilmicin with gentamicin in the therapy of experimental Escherichia coli meningitis. Antimicrob Agents Chemother. 1978 Jun;13(6):899–904. doi: 10.1128/aac.13.6.899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Scheld W. M., Tauber M. G., Zak O., Sande M. A. The influence of dosing schedules and cerebrospinal fluid bactericidal activity on the therapy of bacterial meningitis. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):303–312. doi: 10.1093/jac/15.suppl_a.303. [DOI] [PubMed] [Google Scholar]
  15. Spector R. The transport of gentamicin in the choroid plexus and cerebrospinal fluid. J Pharmacol Exp Ther. 1975 Jul;194(1):82–88. [PubMed] [Google Scholar]
  16. Strausbaugh L. J., Sande M. A. Factors influencing the therapy of experimental Proteus mirabilis meningitis in rabbits. J Infect Dis. 1978 Mar;137(3):251–260. doi: 10.1093/infdis/137.3.251. [DOI] [PubMed] [Google Scholar]
  17. Täuber M. G., Kunz S., Zak O., Sande M. A. Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother. 1989 Apr;33(4):418–423. doi: 10.1128/aac.33.4.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Täuber M. G., Zak O., Scheld W. M., Hengstler B., Sande M. A. The postantibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits. J Infect Dis. 1984 Apr;149(4):575–583. doi: 10.1093/infdis/149.4.575. [DOI] [PubMed] [Google Scholar]
  19. Vogelman B. S., Craig W. A. Postantibiotic effects. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):37–46. doi: 10.1093/jac/15.suppl_a.37. [DOI] [PubMed] [Google Scholar]
  20. Vogelman B., Craig W. A. Kinetics of antimicrobial activity. J Pediatr. 1986 May;108(5 Pt 2):835–840. doi: 10.1016/s0022-3476(86)80754-5. [DOI] [PubMed] [Google Scholar]
  21. Watanabe I., Hodges G. R., Dworzack D. L., Kepes J. J., Duensing G. F. Neurotoxicity of intrathecal gentamicin: a case report and experimental study. Ann Neurol. 1978 Dec;4(6):564–572. doi: 10.1002/ana.410040618. [DOI] [PubMed] [Google Scholar]
  22. Wilson H. D., Haltalin K. C. Ampicillin in Haemophilus influenzae meningitis. Clinicopharmacologic evaluation of intramuscular vs intravenous administration. Am J Dis Child. 1975 Feb;129(2):208–215. doi: 10.1001/archpedi.1975.02120390042009. [DOI] [PubMed] [Google Scholar]
  23. Zhanel G. G., Hoban D. J., Harding G. K. The postantibiotic effect: a review of in vitro and in vivo data. DICP. 1991 Feb;25(2):153–163. doi: 10.1177/106002809102500210. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES